In­cyte scores much need­ed PhI­II suc­cess — and of course it’s de­liv­ered by rux­oli­tinib

In­cyte’s ef­forts to breathe a sec­ond life in­to rux­oli­tinib — its JAK in­hibitor sold in pill form as Jakafi — has been greet­ed with clear, if pre­lim­i­nary and un­sur­pris­ing, Phase III suc­cess.

Topline da­ta from the TRuE-AD2 ce­ments rux­oli­tinib’s foun­da­tion­al im­por­tance for In­cyte, and gives an­a­lysts hope that there might yet be room for growth in a pipeline that’s suf­fered mul­ti­ple R&D set­backs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER